The company said it entered into the 4th amendment to its existing $4.0 billion term loan credit facility on March 21, 2024, and that the purpose was to raise the maximum net leverage ratio covenant.

1. 01

   The company said it entered into the 4th amendment to its existing $4.0 billion term loan credit facility on March 21, 2024, and that the purpose was to raise the maximum net leverage ratio covenant.

2. 02

   The company said the increase in the maximum net leverage ratio under all three amendments applies to the six fiscal quarters ending from June 30, 2024 through September 30, 2025.

3. 03

   The company entered into the 4th amendment to its $2.5 billion 5-year revolving credit agreement and set the date for reducing the Commitments to $2,000,000,000 as the earlier of September 30, 2024 and the date of the sale or spinoff of its Kidney Care business.

4. 04

   The company said Baxter Healthcare SA and Baxter World Trade SRL, as borrowers, entered into the 3rd amendment to the guaranty agreement related to the existing €200 million revolving credit facility, raising the maximum net leverage ratio covenant under the guaranty agreement.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.